Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Rhythm Biosciences Ltd. ( (AU:RHY) ) has shared an announcement.
Rhythm Biosciences will host an investor webinar on 13 May 2026, where CEO and Managing Director Dr David Atkins and his team will brief shareholders on recent progress in its commercial program and share broader market insights. The session, which invites pre-submitted and live questions from investors, underscores the company’s effort to deepen engagement with stakeholders as it advances its cancer diagnostics portfolio and seeks to strengthen its position in the growing market for predictive cancer and risk assessment technologies.
More about Rhythm Biosciences Ltd.
Rhythm Biosciences Ltd is an Australian medical diagnostics company focused on developing simple, affordable blood tests for the early and accurate detection of cancers. Founded in 2017 and headquartered in Melbourne, the company targets global markets through partnerships, with flagship technologies including the ColoSTAT blood test for colorectal cancer and the geneType risk assessment platform serving the preventative healthcare and precision medicine sectors.
Average Trading Volume: 875,885
Technical Sentiment Signal: Sell
Current Market Cap: A$50.97M
For detailed information about RHY stock, go to TipRanks’ Stock Analysis page.